文献速递主动脉疾病

弹簧圈栓塞预防内漏作为腹主动脉瘤腔内修复辅助或后续内漏修复的安全性与疗效

Safety and Efficacy of Coil Embolization for Endoleak Prevention as an Adjunct to Endovascular Repair of Abdominal Aortic Aneurysm or Subsequently for the Repair of Endoleak.
PubMed 文献 · Ann Vasc Surg · 2024-11-22

本研究为多中心回顾性队列研究,纳入2017年1月至2021年12月在日本接受Cerenovus弹簧圈栓塞的306例腹主动脉瘤腔内修复(EVAR)患者,用于预防内漏或内漏再干预。结果显示30天无再干预生存率为96.4%,1年内漏发生率9.5%,动脉瘤相关死亡1年0.3%,全因死亡1年3.3%。

要点

  • 30天无再干预生存率为96.4%(295/306),30天再干预率2.9%(9/306)。
  • 1年内漏发生率9.5%(29/306),动脉瘤相关死亡率0.3%(1/303)。
  • 未报告弹簧圈移位和动脉瘤破裂。

核心结论

  • 使用Cerenovus弹簧圈对腹主动脉瘤EVAR术中预防性栓塞或内漏再干预患者,可获得高30天无再干预生存率及低的目标血管内漏发生和复发率。

研究设计与样本

  • 多中心、回顾性队列研究,纳入2017年1月至2021年12月在日本连续接受Cerenovus弹簧圈栓塞分支动脉的EVAR或内漏再干预患者,共306例,平均年龄76.7±7.8岁,女性16.7%(51/306)。

主要发现

  • 30天无再干预生存率96.4%(295/306);再干预9例(2.9%),心血管死亡2例(0.7%)。
  • 30天非再干预并发症3.9%(12/306),1年12.4%(38/306);30天内漏2.9%(9/306),1年9.5%(29/306)。
  • 30天动脉瘤相关死亡0.0%(0/305),1年0.3%(1/303);30天全因死亡0.7%(2/306),1年3.3%(10/304)。
  • 平均住院时间8.6±7.2天;1例(1/305;0.3%)转为开放修复;未报告弹簧圈移位和动脉瘤破裂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study assessed the real-world safety and efficacy of coil embolization during endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA) for prophylactic endoleak prevention or as a reintervention for endoleak repair, using the Cerenovus family of coils (Cerenovus, Irvine, CA, USA). METHODS: This was a multicenter, retrospective cohort study of consecutive patients who underwent embolization of branching arteries during EVAR of an AAA or as a reintervention for endoleak repair, using Cerenovus coils between January 2017 and December 2021 in Japan. The primary outcome was 30-day reintervention-free survival, defined as cardiovascular mortality or any complication requiring reintervention within 30 days post procedure. Secondary outcomes included conversion to open surgical repair, length of hospitalization, and the following outcomes through 30 days and 1-year post procedure: occurrence of endoleak (Type I-V), reintervention, complications not requiring reintervention, aneurysm-related mortality, coil migration, and all-cause mortality. RESULTS: A total of 306 patients (mean age 76.7 ± 7.8; 16.7% [51/306] female) were included in the study. Infrarenal AAA were most common (175/306; 57.2%), and the mean aneurysm size was 52.1 ± 10.9 mm. At 30 days, reintervention-free survival was achieved in 96.4% (295/306) of the patients; 9 (2.9%) patients required reintervention, and 2 (0.7%) died from cardiovascular causes through 30 days. One (1/305; 0.3%) patient underwent conversion to open repair. The mean length of hospitalization was 8.6 ± 7.2 days. Complications not requiring reintervention occurred in 3.9% (12/306) of the patients through 30-days and 12.4% (38/306) through 1-year. Endoleak occurred in 2.9% (9/306) of the patients at 30 days and 9.5% (29/306) at 1 year. Coil migration and aneurysm rupture were not reported for any patient. Aneurysm-related mortalities occurred in 0.0% (0/305) at 30 days and 0.3% (1/303) at 1 year. All-cause mortalities occurred in 0.7% (2/306) at 30 days and 3.3% (10/304) at 1 year. CONCLUSIONS: This study demonstrated that the use of Cerenovus coils yielded a high rate of 30-day-reintervention-free survival and low rates of type II endoleak occurrence and recurrence at the target vessel through 30 days and 1 year in patients following EVAR of an AAA with coil embolization, either for prophylactic endoleak prevention during EVAR or as a reintervention to repair an endoleak.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Yagami T, Otani T, Hase S, et al. Safety and Efficacy of Coil Embolization for Endoleak Prevention as an Adjunct to Endovascular Repair of Abdominal Aortic Aneurysm or Subsequently for the Repair of Endoleak. Ann Vasc Surg. 2024. PMID: 39581321. doi:10.1016/j.avsg.2024.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。